IPSIndian Journal of Pharmacology
Home  IPS  Feedback Subscribe Top cited articles Login 
Users Online : 295 
Small font sizeDefault font sizeIncrease font size
Navigate Here
 »   Next article
 »   Previous article
 »   Table of Contents

Resource Links
 »   Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
 »   Citation Manager
 »   Access Statistics
 »   Reader Comments
 »   Email Alert *
 »   Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed2106    
    Printed103    
    Emailed1    
    PDF Downloaded128    
    Comments [Add]    
    Cited by others 2    

Recommend this journal

 

 RESEARCH ARTICLE
Year : 2012  |  Volume : 44  |  Issue : 4  |  Page : 448-453

The in vitro anti-viral potential of Setarud (IMOD™), a commercial herbal medicine with protective activity against acquired immune deficiency syndrome in clinical trials


1 Department of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran
2 Faculty of Advanced Sciences and Technologies, University of Isfahan, Isfahan, Iran
3 Member of Young Researchers Club, Islamic Azad University, Falavarjan Branch, Falavarjan, Iran
4 Faculty of Medicine, Tehran University of Medical Sciences TUMS, Tehran, Iran

Correspondence Address:
Mohammad Hossein Modarressi
Faculty of Medicine, Tehran University of Medical Sciences TUMS, Tehran
Iran
Login to access the Email id

Source of Support: Pasteur institute of Iran, Conflict of Interest: None


DOI: 10.4103/0253-7613.99301

Rights and Permissions

Objectives: Setarud (IMOD™) is a herbal medicine with beneficial effect for patients suffering Human immunodeficiency virus (HIV) infection and has been approved for IV (intra venues) injection. The beneficial effect of IMOD administration for acquired immune deficiency syndrome (AIDS) patient has been proved in previous clinical trials. Here the in vitro inhibitory effect of IMOD against HIV-1, Herpes simplex virus (HSV) and murine leukemia viruses (MLV) was evaluated. Materials and Methods: HIV single cycle replication and HSV plaque reduction assays were used to evaluate the anti-viral effect. The level of HIV replication was monitored by p24 capture Enzyme-linked immunosorbent assay (ELISA). The single round infection [with green fluorescent protein (GFP) reporter MLV and HIV], virucidal and time-of-additions (HSV) assays were utilized to determine the mode of anti-viral activity. The toxicity of IMOD for cells was monitored by XTT (sodium 3_-[1 (phenylaminocarbonyl)- 3,4-tetrazolium]-bis (4-methoxy-6-nitro)benzene sulfonic acid) cell proliferation assay kit. Results: IMOD inhibited 50% of HIV-1 and HSV replication (IC 50 ) at 6.5 × 10 -4 and 4.3 × 10 -3 V/V concentrations, respectively. The IC 50 value against HIV-1 and MLV infection were 6 × 10 -4 V/V and 4.9 × 10 -4 V/V. Virucidal assay showed that IMOD reduces the potency of HIV and HSV particles to 41 and 54% of control, respectively. Time-of-addition study revealed that IMOD inhibits the replication of HSV at a stage after penetration of virions to the target cells. Conclusions: Data from this study indicate that IMOD has significant anti-viral activity against HIV, HSV and MLV. Setarud could be subjected to further investigation after isolation of the constituents and determination of the toxic components.






[FULL TEXT] [PDF]*


        
Print this article     Email this article

Site Map | Home | Contact Us | Feedback | Copyright and Disclaimer
Online since 20th July '04
Published by Wolters Kluwer - Medknow